Glioma Market Insights
A glioma is a central nervous system tumor that arises from glial stem or progenitor cells. Glial cells are a type of cell widely present in the nervous system. Gliomas mainly occur in the brain and, rarely, in the spinal cord.
Glioma Epidemiology Insights (2022)
The Glioma Total incident cases in the 7MM were ~47K cases in 2022
Glioma Epidemiology Segmentation in the 7MM from 2019 to 2032
- Total Incident Population
- Grade-specific Incident Population
- Type-specific Population of High-grade Glioma
- Type-specific Population of Low-grade Glioma
- Age-specific Population
- Glioma Cases Based on Molecular Alterations
Glioma Market Insight (2022)
The Glioma Market size in the 7MM was valued ~USD 1 billion in 2022
Glioma Market Strengths
- Rise in the aging population
- Improvement in genomics and proteomics
Glioma Market Opportunities
- Increasing incidence trend
- Substantial market opportunity for key players
Glioma Emerging Drugs and Key Companies
- Regorafenib: Bayer
- ONC201: Chimerix
- AV-GBM-1: Aivita Biomedical
- Enzastaurin (DB-102): Denovo Biopharma
- DCVax-L: Northwest Therapeutics
- Ofranergene Obadenovec (VB-111): VBL Therapeutics
- LAM561 (2-OHOA): Laminar Pharmaceuticals
- MEDI4736 (durvalumab): MedImmune
- Tasadenoturev (DNX-2401): DNAtrix
- ITI-1000 (pp65 DC Vaccine): Immunomic Therapeutics
- IGV-001: Imvax
- SurVaxM: MimiVax
- Berubicin: CNS Pharmaceuticals
- GLIOVAC (Sitoiganap): Epitopoietic Research Corporation (ERC)
- Lerapolturev + Pembrolizumab: Istari Oncology
- SONALA-001 + Exablate 2.0 Device: SonALAsense
- VAL-083 (dianhydrogalactitol): Kintara Therapeutics
- Pomalidomide: Bristol Myers Squibb
- MDNA55: Medicenna Therapeutics
- BMX-001: BioMimetix
- Lenvatinib ± Pembrolizumab: Eisai and Merck Sharp & Dohme
- Paxalisib (GDC-0084): Kazia Therapeutics
- OKN-007: Oblato
- Temferon: Genenta Science
- EO2401: Enterome
- INO-5401+ INO-9012+ LIBTAYO (cemiplimab): Inovio Pharmaceuticals
- Selinexor (KPT-330): Karyopharm Therapeutics
- VBI-1901: VBI Vaccines
- NOX-A12 (Olaptesed Pegol): TME Pharma
- Tovorafenib (DAY101): Day One Biopharmaceuticals
- Vorasidenib (AG-881): Servier
- Eflornithine: Orbus Therapeutics
- TVI-Brain-1: TVAX Biomedical
- AB-218: AnHeart Therapeutics
- BGB-290: Beigene
- Mirdametinib: SpringWorks Therapeutics
- FT-2102 (Olutasidenib): Forma Therapeutics
- Vinblastine + Bevacizumab: Hoffmann-La Roche
- Cobimetinib: Hoffmann-La Roche
- PEMAZYRE (Pemigatinib): Incyte Corporation
- VERZENIO (abemaciclib): Eli Lilly, and others